VentureMed Group Raises Bridge Financing and Embarks on 2023 Objectives
Summary
MINNEAPOLIS, Jan. 31, 2023 /PRNewswire/ -- VentureMed Group, Inc., a privately held medical device innovator in access management for arteriovenous (AV) fistulas and grafts and vessel preparation for interventional treatment of peripheral arterial disease (PAD) announced today that the company has raised bridge financing to support its 2023 objectives.Endeavour Vision and RiverVest Venture Partners co-led the bridge funding, which covers five key objectives for 2023: Build upon existing library of publications and scientific presentations Expand and generate awareness of VentureMeds "Disparities in Care" Initiative"We continue to be impressed with the planning, execution and deliverables from the VentureMed team," said Alexander Schmitz, partner at Endeavour Vision. "We see 2023 as a pivotal year for the company with tremendous growth opportunities in both the AV and PAD segments". "About VentureMed Group, Inc. and the FLEX Vessel Prep SystemVentureMed Group, Inc. develops and markets innovative endovascular medical devices to solve unmet medical needs in the treatment of stenoses of AV fistulas and grafts and PAD. FLEX was designed to provide controlled and predictable pre-treatment to optimize outcomes in complex stenoses & lesions of any length or vessel morphology. The FLEX VP System received CE Mark and 510(k) clearance from the US Food and Drug Administration.